Study details
Enrolling now
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
Rise Therapeutics LLC
NCT IDNCT05666960ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
36
Study length
about 2.7 years
Ages
18–65
Locations
4 sites in CA, FL, MN
About this study
This trial is testing the safety and tolerability of R-3750, an oral probiotic, in people with mild to moderate ulcerative colitis. Participants will take R-3750 orally and provide information about their condition through patient reports and doctor evaluations. Blood and stool tests will also be done to measure inflammation and assess R-3750 levels in the gut.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take R-3750
PhasePhase 1
Routeoral
Primary goalTo assess the tolerability of R-3750
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
oral
Endpoints
Primary: To assess the tolerability of R-3750
Body systems
Gastroenterology